These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8588236)

  • 1. Therapeutic drug monitoring of cyclosporin G.
    Yatscoff RW; Langman L; LeGatt DF
    Ther Drug Monit; 1995 Dec; 17(6):655-9. PubMed ID: 8588236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assurance program for cyclosporin G (OG37-325).
    Yatscoff RW; Chackowsky P
    Ther Drug Monit; 1995 Aug; 17(4):342-7. PubMed ID: 7482687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients.
    Gruber SA; Gallichio M; Rosano TG; Kaplan SS; Hughes SE; Urbauer DL; Singh TP; Lempert N; Conti DJ; Stein DS; Drusano G
    J Clin Pharmacol; 1997 Jul; 37(7):575-86. PubMed ID: 9243350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines.
    Langman LJ; Yatscoff RW
    Ther Drug Monit; 1994 Oct; 16(5):450-7. PubMed ID: 7846742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A.
    Burdmann EA; Andoh TF; Rosen S; Lindsley J; Munar MY; Elzinga LW; Bennett WM
    Kidney Int; 1994 Mar; 45(3):684-91. PubMed ID: 8196271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in renal transplant recipients.
    Langman LJ; Leichtman AB; Weitzel WF; Yatscoff RW
    Clin Chem; 1994 Apr; 40(4):613-6. PubMed ID: 8149619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin C2hour monitoring after renal transplantation.
    Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Glander P; Böhler T; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):477-81. PubMed ID: 14703954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method.
    Grundmann M; Perinova I; Brozmanova H; Koristkova B; Safarcik K
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):87-92. PubMed ID: 20137760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture.
    Ellouk-Achard S; Martin C; Pham-Huy C; Duc HT; Thevenin M; Dutertre-Catella H; Warnet JM; Claude JR
    Arch Toxicol; 1997; 71(7):437-42. PubMed ID: 9209689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactivities of cyclosporin G (NVa2 cyclosporin) and metabolites in cyclosporin A immunoassays.
    Yatscoff RW; Langman LJ; LeGatt DF
    Clin Chem; 1993 Jun; 39(6):1089-92. PubMed ID: 8504544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of effects of cyclosporins A and G on collagen arthritis in mice.
    Takagishi K; Yamamoto M; Miyahara H; Hotokebuchi T; Kaibara N
    Agents Actions; 1992 Nov; 37(3-4):284-9. PubMed ID: 1295377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
    Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V; Lalić Z; Nađ-Škegro S; Lebo A; Granić P; Lovrić M; Pasini J; Božina N
    Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of therapeutic drug monitoring to optimise immunosuppressive therapy.
    Tsunoda SM; Aweeka FT
    Clin Pharmacokinet; 1996 Feb; 30(2):107-40. PubMed ID: 8906895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.
    Kotani T; Makino S; Takeuchi T; Kagitani M; Shoda T; Hata A; Tabushi Y; Hanafusa T
    J Rheumatol; 2008 Feb; 35(2):254-9. PubMed ID: 18085732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the immunosuppressive effects of cyclosporine A and cyclosporine G in vivo and in vitro.
    Rayat G; Yatscoff R; Silverman R; McKenna R
    Transplantation; 1993 Mar; 55(3):623-6. PubMed ID: 8456482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine: update on pharmacology, analytical techniques and therapeutic monitoring.
    Santori L; Rastelli M; Arena B; Morleo MA
    Boll Chim Farm; 1997 Oct; 136(9):577-88. PubMed ID: 9440351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two new cyclosporin folds observed in the structures of the immunosuppressant cyclosporin G and the formyl peptide receptor antagonist cyclosporin H at ultra-high resolution.
    Potter B; Palmer RA; Withnall R; Jenkins TC; Chowdhry BZ
    Org Biomol Chem; 2003 May; 1(9):1466-74. PubMed ID: 12926274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.